{"id":475797,"date":"2020-03-24T13:40:02","date_gmt":"2020-03-24T13:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475797"},"modified":"2020-03-24T13:40:02","modified_gmt":"2020-03-24T13:40:02","slug":"cold-agglutinin-disease-market-insights-epidemiology-and-market-forecast-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cold-agglutinin-disease-market-insights-epidemiology-and-market-forecast-2030-delveinsight_475797.html","title":{"rendered":"Cold Agglutinin Disease Market Insights, Epidemiology and Market Forecast 2030 | DelveInsight"},"content":{"rendered":"
\"Cold<\/a><\/div>\n
DelveInsight’s “Cold Agglutinin Disease (CAD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Cold Agglutinin Disease (CAD), historical and forecasted epidemiology as well as the Cold Agglutinin Disease (CAD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

(Albany, US) DelveInsight<\/strong> launched a new report on Cold Agglutinin Disease (CAD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/span><\/p>\n

DelveInsight’s “Cold Agglutinin Disease (CAD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>“<\/span> report delivers an in-depth understanding of the Cold Agglutinin Disease (CAD), historical and forecasted epidemiology as well as the Cold Agglutinin Disease (CAD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the report:<\/strong>
1. Cold Agglutinin Disease frequency is usually more in females than in males. The male to female ratio is around 45:55.<\/span>
2. The United States has the highest percentage of Cold Agglutinin Disease prevalent diagnosed & treated patients.<\/span>
3. The prevalence of Cold Agglutinin Disease in Europe is assumed to be about 10 cases per million.<\/span><\/p>\n

Key benefits of the report:<\/strong><\/p>\n

1. Cold Agglutinin Disease market report covers a descriptive overview and comprehensive insight of the Cold Agglutinin Disease epidemiology and Cold Agglutinin Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span>
2. Cold Agglutinin Disease market report provides insights on the current and emerging therapies.<\/span>
3. Cold Agglutinin Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. Cold Agglutinin Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cold Agglutinin Disease market.<\/span><\/span><\/p>\n

\"\"<\/strong><\/span><\/span><\/p>\n

Request for sample pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/cold-agglutinin-disease-cad-market<\/span><\/span><\/p>\n

The key players in Cold Agglutinin Disease market are:<\/strong>
1. Sanofi
2. Apellis Pharmaceuticals
3. Janssen Pharmaceutical<\/p>\n

The launch of the emerging therapies is expected to significantly impact the Cold Agglutinin Disease treatment scenario in the upcoming years:-<\/strong><\/p>\n

Drugs covered:<\/span><\/strong>
1. Sutimlimab<\/span>
2. APL-2<\/span>
3. Bortezomib<\/span><\/span><\/span><\/p>\n

Table of contents<\/strong>
1. Key Insights<\/span>
2. Cold Agglutinin Disease Market Overview at a Glance<\/span>
3. Executive summary<\/span>
4. Organizations<\/span>
5. Cold Agglutinin Disease Epidemiology and Market Methodology<\/span>
6. Cold Agglutinin Disease Background and Overview<\/span>
7. Cold Agglutinin Disease Epidemiology and Patient Population<\/span>
8. Cold Agglutinin Disease Total Prevalent cases in 7MM<\/span>
9. Country Wise-Epidemiology of Cold Agglutinin Disease<\/span>
9.1.1. United States<\/span>
9.1.2. EU5 Countries<\/span>
9.1.3. Germany<\/span>
9.1.4. France<\/span>
9.1.5. Italy<\/span>
9.1.6. Spain<\/span>
9.1.7. The United Kingdom<\/span>
9.1.8. Japan<\/span>
10. Cold Agglutinin Disease Treatment Algorithm, Current Treatment, and Medical Practices<\/span>
11. Unmet Needs<\/span>
12. Cold Agglutinin Disease Emerging Therapies<\/span>
12.1.1. Key Cross Competition<\/span>
12.1.2. Sutimlimab: Sanofi<\/span>
12.1.3. APL-2: Apellis Pharmaceuticals<\/span>
12.1.4. Bortezomib: Janssen Pharmaceutical<\/span>
13. Cold Agglutinin Disease 7 Major Market Analysis<\/span>
13.1.1. Key Findings<\/span>
14. Seven Major Market Outlook<\/span>
14.1.1. United States Market Size<\/span>
14.1.2. Germany<\/span>
14.1.3. France<\/span>
14.1.4. Italy<\/span>
14.1.5. Spain<\/span>
14.1.6. United Kingdom<\/span>
14.1.7. Japan<\/span>
15. Market Drivers<\/span>
16. Market Barriers<\/span>
17. SWOT<\/span>
18. Case Studies<\/span>
19. KOL Views<\/span>
20. Appendix<\/span>
21. DelveInsight Capabilities<\/span>
22. Disclaimer<\/span>
23. About DelveInsight<\/span><\/p>\n

Download a free sample report<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/cold-agglutinin-disease-cad-market<\/span><\/p>\n

Related reports:<\/strong><\/p>\n

Cold Agglutinin Disease (CAD) Pipeline Insight, 2020<\/a><\/strong><\/p>\n

Cold Agglutinin Disease (CAD) – Epidemiology Forecast to 2030<\/a><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight’s “Cold Agglutinin Disease (CAD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Cold Agglutinin Disease (CAD), historical and forecasted epidemiology as well as the Cold Agglutinin Disease (CAD) market trends in the United … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-475797","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=475797"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475797\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=475797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=475797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=475797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}